nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—ESR2—uterine cancer	0.203	0.437	CbGaD
Raloxifene—CYP19A1—uterine cancer	0.136	0.293	CbGaD
Raloxifene—ESR1—uterine cancer	0.125	0.27	CbGaD
Raloxifene—ESR1—Medroxyprogesterone Acetate—uterine cancer	0.11	0.306	CbGbCtD
Raloxifene—SIGMAR1—Progesterone—uterine cancer	0.0901	0.251	CbGbCtD
Raloxifene—ESR1—Progesterone—uterine cancer	0.0728	0.203	CbGbCtD
Raloxifene—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0278	0.0775	CbGbCtD
Raloxifene—CYP2C8—Progesterone—uterine cancer	0.0184	0.0514	CbGbCtD
Raloxifene—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0113	0.0314	CbGbCtD
Raloxifene—CYP2C8—Etoposide—uterine cancer	0.00825	0.023	CbGbCtD
Raloxifene—CYP3A4—Progesterone—uterine cancer	0.00748	0.0208	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—uterine cancer	0.00743	0.0207	CbGbCtD
Raloxifene—CYP19A1—corpus luteum—uterine cancer	0.0061	0.129	CbGeAlD
Raloxifene—CYP3A4—Etoposide—uterine cancer	0.00335	0.00932	CbGbCtD
Raloxifene—CYP19A1—semen—uterine cancer	0.00286	0.0605	CbGeAlD
Raloxifene—ESR2—oviduct—uterine cancer	0.00266	0.0563	CbGeAlD
Raloxifene—CYP3A4—Doxorubicin—uterine cancer	0.00228	0.00636	CbGbCtD
Raloxifene—EBP—uterine cervix—uterine cancer	0.0019	0.0403	CbGeAlD
Raloxifene—ESR1—oviduct—uterine cancer	0.00182	0.0386	CbGeAlD
Raloxifene—EBP—uterus—uterine cancer	0.00159	0.0336	CbGeAlD
Raloxifene—EBP—female reproductive system—uterine cancer	0.00143	0.0302	CbGeAlD
Raloxifene—SIGMAR1—Levonorgestrel—Progesterone—uterine cancer	0.00122	1	CbGdCrCtD
Raloxifene—AOX1—myometrium—uterine cancer	0.00082	0.0174	CbGeAlD
Raloxifene—ESR2—epithelium—uterine cancer	0.000668	0.0141	CbGeAlD
Raloxifene—ESR2—uterine cervix—uterine cancer	0.000663	0.014	CbGeAlD
Raloxifene—SIGMAR1—myometrium—uterine cancer	0.00066	0.014	CbGeAlD
Raloxifene—HTR2B—myometrium—uterine cancer	0.000658	0.0139	CbGeAlD
Raloxifene—ESR2—smooth muscle tissue—uterine cancer	0.000644	0.0136	CbGeAlD
Raloxifene—AOX1—uterine cervix—uterine cancer	0.000638	0.0135	CbGeAlD
Raloxifene—ESR2—renal system—uterine cancer	0.00062	0.0131	CbGeAlD
Raloxifene—AOX1—decidua—uterine cancer	0.000608	0.0129	CbGeAlD
Raloxifene—ESR2—endometrium—uterine cancer	0.000599	0.0127	CbGeAlD
Raloxifene—AOX1—renal system—uterine cancer	0.000597	0.0126	CbGeAlD
Raloxifene—ESR1—myometrium—uterine cancer	0.000583	0.0123	CbGeAlD
Raloxifene—AOX1—endometrium—uterine cancer	0.000577	0.0122	CbGeAlD
Raloxifene—AOX1—mammalian vulva—uterine cancer	0.000558	0.0118	CbGeAlD
Raloxifene—ESR2—uterus—uterine cancer	0.000552	0.0117	CbGeAlD
Raloxifene—AOX1—uterus—uterine cancer	0.000532	0.0113	CbGeAlD
Raloxifene—SIGMAR1—uterine cervix—uterine cancer	0.000513	0.0109	CbGeAlD
Raloxifene—HTR2B—uterine cervix—uterine cancer	0.000512	0.0108	CbGeAlD
Raloxifene—SIGMAR1—smooth muscle tissue—uterine cancer	0.000499	0.0106	CbGeAlD
Raloxifene—HTR2B—smooth muscle tissue—uterine cancer	0.000498	0.0105	CbGeAlD
Raloxifene—ESR2—female reproductive system—uterine cancer	0.000496	0.0105	CbGeAlD
Raloxifene—SIGMAR1—decidua—uterine cancer	0.000489	0.0104	CbGeAlD
Raloxifene—HTR2B—decidua—uterine cancer	0.000488	0.0103	CbGeAlD
Raloxifene—AOX1—female reproductive system—uterine cancer	0.000478	0.0101	CbGeAlD
Raloxifene—CYP19A1—endometrium—uterine cancer	0.000472	0.01	CbGeAlD
Raloxifene—SIGMAR1—endometrium—uterine cancer	0.000464	0.00983	CbGeAlD
Raloxifene—HTR2B—endometrium—uterine cancer	0.000463	0.00981	CbGeAlD
Raloxifene—ESR1—epithelium—uterine cancer	0.000458	0.00969	CbGeAlD
Raloxifene—ESR1—uterine cervix—uterine cancer	0.000454	0.00961	CbGeAlD
Raloxifene—ESR2—female gonad—uterine cancer	0.000452	0.00956	CbGeAlD
Raloxifene—SIGMAR1—mammalian vulva—uterine cancer	0.000449	0.00951	CbGeAlD
Raloxifene—ESR2—vagina—uterine cancer	0.000449	0.00951	CbGeAlD
Raloxifene—ESR1—smooth muscle tissue—uterine cancer	0.000441	0.00934	CbGeAlD
Raloxifene—CYP19A1—uterus—uterine cancer	0.000435	0.00921	CbGeAlD
Raloxifene—AOX1—female gonad—uterine cancer	0.000435	0.00921	CbGeAlD
Raloxifene—ESR1—decidua—uterine cancer	0.000432	0.00915	CbGeAlD
Raloxifene—AOX1—vagina—uterine cancer	0.000432	0.00915	CbGeAlD
Raloxifene—SIGMAR1—uterus—uterine cancer	0.000428	0.00906	CbGeAlD
Raloxifene—HTR2B—uterus—uterine cancer	0.000427	0.00904	CbGeAlD
Raloxifene—ESR1—renal system—uterine cancer	0.000425	0.00899	CbGeAlD
Raloxifene—ESR1—endometrium—uterine cancer	0.00041	0.00869	CbGeAlD
Raloxifene—CYP19A1—female reproductive system—uterine cancer	0.000391	0.00828	CbGeAlD
Raloxifene—HTR2B—female reproductive system—uterine cancer	0.000384	0.00812	CbGeAlD
Raloxifene—ESR1—uterus—uterine cancer	0.000378	0.00801	CbGeAlD
Raloxifene—CYP19A1—female gonad—uterine cancer	0.000356	0.00754	CbGeAlD
Raloxifene—SIGMAR1—female gonad—uterine cancer	0.00035	0.00741	CbGeAlD
Raloxifene—CYP2C8—renal system—uterine cancer	0.00035	0.0074	CbGeAlD
Raloxifene—SIGMAR1—vagina—uterine cancer	0.000348	0.00736	CbGeAlD
Raloxifene—HTR2B—vagina—uterine cancer	0.000347	0.00735	CbGeAlD
Raloxifene—ESR1—female reproductive system—uterine cancer	0.00034	0.0072	CbGeAlD
Raloxifene—CYP2C8—endometrium—uterine cancer	0.000338	0.00716	CbGeAlD
Raloxifene—CYP2B6—renal system—uterine cancer	0.000314	0.00664	CbGeAlD
Raloxifene—ESR1—female gonad—uterine cancer	0.000309	0.00655	CbGeAlD
Raloxifene—ESR1—vagina—uterine cancer	0.000308	0.00651	CbGeAlD
Raloxifene—ESR2—lymph node—uterine cancer	0.00029	0.00615	CbGeAlD
Raloxifene—CYP2C8—female reproductive system—uterine cancer	0.00028	0.00593	CbGeAlD
Raloxifene—AOX1—lymph node—uterine cancer	0.00028	0.00592	CbGeAlD
Raloxifene—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.000272	0.00279	CcSEcCtD
Raloxifene—Vaginal discharge—Doxorubicin—uterine cancer	0.000266	0.00273	CcSEcCtD
Raloxifene—Flatulence—Progesterone—uterine cancer	0.000263	0.0027	CcSEcCtD
Raloxifene—Cardiac disorder—Medroxyprogesterone Acetate—uterine cancer	0.000258	0.00265	CcSEcCtD
Raloxifene—Muscle spasms—Progesterone—uterine cancer	0.000256	0.00263	CcSEcCtD
Raloxifene—CYP2C8—vagina—uterine cancer	0.000253	0.00536	CbGeAlD
Raloxifene—Embolism—Doxorubicin—uterine cancer	0.000252	0.00259	CcSEcCtD
Raloxifene—Angiopathy—Medroxyprogesterone Acetate—uterine cancer	0.000252	0.00259	CcSEcCtD
Raloxifene—Neuralgia—Epirubicin—uterine cancer	0.000252	0.00259	CcSEcCtD
Raloxifene—CYP2B6—female reproductive system—uterine cancer	0.000251	0.00532	CbGeAlD
Raloxifene—Laryngitis—Epirubicin—uterine cancer	0.000243	0.00249	CcSEcCtD
Raloxifene—Pneumonia—Dactinomycin—uterine cancer	0.000243	0.00249	CcSEcCtD
Raloxifene—Vertigo—Progesterone—uterine cancer	0.00024	0.00246	CcSEcCtD
Raloxifene—Syncope—Progesterone—uterine cancer	0.000239	0.00246	CcSEcCtD
Raloxifene—Flatulence—Medroxyprogesterone Acetate—uterine cancer	0.000238	0.00245	CcSEcCtD
Raloxifene—CYP3A4—renal system—uterine cancer	0.000237	0.00502	CbGeAlD
Raloxifene—Vaginal haemorrhage—Epirubicin—uterine cancer	0.000236	0.00243	CcSEcCtD
Raloxifene—Loss of consciousness—Progesterone—uterine cancer	0.000234	0.00241	CcSEcCtD
Raloxifene—Neuralgia—Doxorubicin—uterine cancer	0.000233	0.00239	CcSEcCtD
Raloxifene—Cough—Progesterone—uterine cancer	0.000233	0.00239	CcSEcCtD
Raloxifene—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.000232	0.00239	CcSEcCtD
Raloxifene—CYP19A1—lymph node—uterine cancer	0.000229	0.00485	CbGeAlD
Raloxifene—CYP2B6—vagina—uterine cancer	0.000227	0.00481	CbGeAlD
Raloxifene—Chest pain—Progesterone—uterine cancer	0.000227	0.00233	CcSEcCtD
Raloxifene—Myalgia—Progesterone—uterine cancer	0.000227	0.00233	CcSEcCtD
Raloxifene—Arthralgia—Progesterone—uterine cancer	0.000227	0.00233	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000225	0.00232	CcSEcCtD
Raloxifene—SIGMAR1—lymph node—uterine cancer	0.000225	0.00476	CbGeAlD
Raloxifene—Laryngitis—Doxorubicin—uterine cancer	0.000225	0.00231	CcSEcCtD
Raloxifene—HTR2B—lymph node—uterine cancer	0.000224	0.00475	CbGeAlD
Raloxifene—Vaginal haemorrhage—Doxorubicin—uterine cancer	0.000219	0.00225	CcSEcCtD
Raloxifene—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.000217	0.00223	CcSEcCtD
Raloxifene—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.000217	0.00223	CcSEcCtD
Raloxifene—Infection—Progesterone—uterine cancer	0.000216	0.00222	CcSEcCtD
Raloxifene—Pharyngitis—Dactinomycin—uterine cancer	0.000215	0.00221	CcSEcCtD
Raloxifene—Shock—Progesterone—uterine cancer	0.000214	0.0022	CcSEcCtD
Raloxifene—Nervous system disorder—Progesterone—uterine cancer	0.000213	0.00219	CcSEcCtD
Raloxifene—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.000212	0.00218	CcSEcCtD
Raloxifene—Skin disorder—Progesterone—uterine cancer	0.000211	0.00217	CcSEcCtD
Raloxifene—Hyperhidrosis—Progesterone—uterine cancer	0.00021	0.00216	CcSEcCtD
Raloxifene—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.000206	0.00211	CcSEcCtD
Raloxifene—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.000206	0.00211	CcSEcCtD
Raloxifene—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.000206	0.00211	CcSEcCtD
Raloxifene—Neoplasm malignant—Epirubicin—uterine cancer	0.000205	0.0021	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000204	0.0021	CcSEcCtD
Raloxifene—Flushing—Dactinomycin—uterine cancer	0.000201	0.00206	CcSEcCtD
Raloxifene—Breast pain—Epirubicin—uterine cancer	0.0002	0.00206	CcSEcCtD
Raloxifene—Vasodilation procedure—Epirubicin—uterine cancer	0.000199	0.00204	CcSEcCtD
Raloxifene—Vasodilation—Epirubicin—uterine cancer	0.000199	0.00204	CcSEcCtD
Raloxifene—ESR1—lymph node—uterine cancer	0.000199	0.00421	CbGeAlD
Raloxifene—Musculoskeletal discomfort—Progesterone—uterine cancer	0.000198	0.00204	CcSEcCtD
Raloxifene—Insomnia—Progesterone—uterine cancer	0.000197	0.00202	CcSEcCtD
Raloxifene—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000196	0.00201	CcSEcCtD
Raloxifene—Shock—Medroxyprogesterone Acetate—uterine cancer	0.000194	0.00199	CcSEcCtD
Raloxifene—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000193	0.00199	CcSEcCtD
Raloxifene—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000193	0.00198	CcSEcCtD
Raloxifene—Dyspepsia—Progesterone—uterine cancer	0.000192	0.00197	CcSEcCtD
Raloxifene—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000192	0.00197	CcSEcCtD
Raloxifene—Cough increased—Epirubicin—uterine cancer	0.000191	0.00196	CcSEcCtD
Raloxifene—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000191	0.00196	CcSEcCtD
Raloxifene—CYP3A4—female reproductive system—uterine cancer	0.00019	0.00402	CbGeAlD
Raloxifene—Neoplasm malignant—Doxorubicin—uterine cancer	0.00019	0.00195	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Progesterone—uterine cancer	0.000188	0.00193	CcSEcCtD
Raloxifene—Pain—Progesterone—uterine cancer	0.000186	0.00191	CcSEcCtD
Raloxifene—Breast pain—Doxorubicin—uterine cancer	0.000186	0.00191	CcSEcCtD
Raloxifene—Vasodilation—Doxorubicin—uterine cancer	0.000184	0.00189	CcSEcCtD
Raloxifene—Vasodilation procedure—Doxorubicin—uterine cancer	0.000184	0.00189	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00018	0.00185	CcSEcCtD
Raloxifene—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000178	0.00183	CcSEcCtD
Raloxifene—Gastrointestinal pain—Progesterone—uterine cancer	0.000178	0.00183	CcSEcCtD
Raloxifene—Cough increased—Doxorubicin—uterine cancer	0.000177	0.00182	CcSEcCtD
Raloxifene—Pneumonia—Etoposide—uterine cancer	0.000176	0.0018	CcSEcCtD
Raloxifene—Vaginal inflammation—Epirubicin—uterine cancer	0.000175	0.0018	CcSEcCtD
Raloxifene—Pulmonary embolism—Epirubicin—uterine cancer	0.000175	0.0018	CcSEcCtD
Raloxifene—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000174	0.00178	CcSEcCtD
Raloxifene—Abdominal pain—Progesterone—uterine cancer	0.000172	0.00177	CcSEcCtD
Raloxifene—Body temperature increased—Progesterone—uterine cancer	0.000172	0.00177	CcSEcCtD
Raloxifene—Cystitis noninfective—Epirubicin—uterine cancer	0.000171	0.00175	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00017	0.00175	CcSEcCtD
Raloxifene—Cystitis—Epirubicin—uterine cancer	0.000169	0.00173	CcSEcCtD
Raloxifene—Vaginal infection—Epirubicin—uterine cancer	0.000165	0.0017	CcSEcCtD
Raloxifene—Vaginal inflammation—Doxorubicin—uterine cancer	0.000162	0.00166	CcSEcCtD
Raloxifene—Pulmonary embolism—Doxorubicin—uterine cancer	0.000162	0.00166	CcSEcCtD
Raloxifene—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000161	0.00166	CcSEcCtD
Raloxifene—Cramps of lower extremities—Epirubicin—uterine cancer	0.000161	0.00165	CcSEcCtD
Raloxifene—Myalgia—Dactinomycin—uterine cancer	0.00016	0.00165	CcSEcCtD
Raloxifene—Bladder pain—Epirubicin—uterine cancer	0.000158	0.00162	CcSEcCtD
Raloxifene—Cystitis noninfective—Doxorubicin—uterine cancer	0.000158	0.00162	CcSEcCtD
Raloxifene—Cystitis—Doxorubicin—uterine cancer	0.000156	0.00161	CcSEcCtD
Raloxifene—Hypoaesthesia—Etoposide—uterine cancer	0.000156	0.0016	CcSEcCtD
Raloxifene—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000156	0.0016	CcSEcCtD
Raloxifene—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000156	0.0016	CcSEcCtD
Raloxifene—Urinary tract disorder—Etoposide—uterine cancer	0.000155	0.00159	CcSEcCtD
Raloxifene—Urethral disorder—Etoposide—uterine cancer	0.000154	0.00158	CcSEcCtD
Raloxifene—Infection—Dactinomycin—uterine cancer	0.000153	0.00157	CcSEcCtD
Raloxifene—Vaginal infection—Doxorubicin—uterine cancer	0.000153	0.00157	CcSEcCtD
Raloxifene—Thrombocytopenia—Dactinomycin—uterine cancer	0.000151	0.00155	CcSEcCtD
Raloxifene—Diarrhoea—Progesterone—uterine cancer	0.000149	0.00153	CcSEcCtD
Raloxifene—Cramps of lower extremities—Doxorubicin—uterine cancer	0.000149	0.00153	CcSEcCtD
Raloxifene—Bladder pain—Doxorubicin—uterine cancer	0.000146	0.0015	CcSEcCtD
Raloxifene—Diabetes mellitus—Epirubicin—uterine cancer	0.000146	0.0015	CcSEcCtD
Raloxifene—Flushing—Etoposide—uterine cancer	0.000145	0.00149	CcSEcCtD
Raloxifene—Cardiac disorder—Etoposide—uterine cancer	0.000145	0.00149	CcSEcCtD
Raloxifene—Dizziness—Progesterone—uterine cancer	0.000144	0.00148	CcSEcCtD
Raloxifene—Angiopathy—Etoposide—uterine cancer	0.000142	0.00146	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00014	0.00144	CcSEcCtD
Raloxifene—Vomiting—Progesterone—uterine cancer	0.000138	0.00142	CcSEcCtD
Raloxifene—Rash—Progesterone—uterine cancer	0.000137	0.00141	CcSEcCtD
Raloxifene—Dermatitis—Progesterone—uterine cancer	0.000137	0.00141	CcSEcCtD
Raloxifene—Headache—Progesterone—uterine cancer	0.000136	0.0014	CcSEcCtD
Raloxifene—Hot flush—Epirubicin—uterine cancer	0.000136	0.00139	CcSEcCtD
Raloxifene—Diabetes mellitus—Doxorubicin—uterine cancer	0.000135	0.00139	CcSEcCtD
Raloxifene—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000135	0.00139	CcSEcCtD
Raloxifene—Menopausal symptoms—Epirubicin—uterine cancer	0.000135	0.00138	CcSEcCtD
Raloxifene—Pain—Dactinomycin—uterine cancer	0.000132	0.00135	CcSEcCtD
Raloxifene—Muscle spasms—Etoposide—uterine cancer	0.000131	0.00135	CcSEcCtD
Raloxifene—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00013	0.00134	CcSEcCtD
Raloxifene—Cerebrovascular accident—Epirubicin—uterine cancer	0.00013	0.00133	CcSEcCtD
Raloxifene—Nausea—Progesterone—uterine cancer	0.000129	0.00133	CcSEcCtD
Raloxifene—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000126	0.00129	CcSEcCtD
Raloxifene—Hot flush—Doxorubicin—uterine cancer	0.000126	0.00129	CcSEcCtD
Raloxifene—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000125	0.00129	CcSEcCtD
Raloxifene—Migraine—Epirubicin—uterine cancer	0.000125	0.00128	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—uterine cancer	0.000125	0.00128	CcSEcCtD
Raloxifene—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000124	0.00128	CcSEcCtD
Raloxifene—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000124	0.00128	CcSEcCtD
Raloxifene—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000124	0.00127	CcSEcCtD
Raloxifene—Vertigo—Etoposide—uterine cancer	0.000123	0.00126	CcSEcCtD
Raloxifene—Body temperature increased—Dactinomycin—uterine cancer	0.000122	0.00125	CcSEcCtD
Raloxifene—Abdominal pain—Dactinomycin—uterine cancer	0.000122	0.00125	CcSEcCtD
Raloxifene—Loss of consciousness—Etoposide—uterine cancer	0.00012	0.00123	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—uterine cancer	0.00012	0.00123	CcSEcCtD
Raloxifene—Cough—Etoposide—uterine cancer	0.000119	0.00122	CcSEcCtD
Raloxifene—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000117	0.0012	CcSEcCtD
Raloxifene—Chest pain—Etoposide—uterine cancer	0.000116	0.00119	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—uterine cancer	0.000116	0.00119	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000115	0.00118	CcSEcCtD
Raloxifene—Breast disorder—Epirubicin—uterine cancer	0.000115	0.00118	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000114	0.00117	CcSEcCtD
Raloxifene—Infection—Etoposide—uterine cancer	0.000111	0.00114	CcSEcCtD
Raloxifene—Influenza—Epirubicin—uterine cancer	0.00011	0.00113	CcSEcCtD
Raloxifene—Thrombocytopenia—Etoposide—uterine cancer	0.000109	0.00112	CcSEcCtD
Raloxifene—Skin disorder—Etoposide—uterine cancer	0.000108	0.00111	CcSEcCtD
Raloxifene—Hyperhidrosis—Etoposide—uterine cancer	0.000108	0.00111	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—uterine cancer	0.000106	0.00109	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000106	0.00109	CcSEcCtD
Raloxifene—Bronchitis—Epirubicin—uterine cancer	0.000106	0.00108	CcSEcCtD
Raloxifene—Diarrhoea—Dactinomycin—uterine cancer	0.000105	0.00108	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—uterine cancer	0.000102	0.00104	CcSEcCtD
Raloxifene—Weight increased—Epirubicin—uterine cancer	9.99e-05	0.00103	CcSEcCtD
Raloxifene—Pneumonia—Epirubicin—uterine cancer	9.84e-05	0.00101	CcSEcCtD
Raloxifene—Vomiting—Dactinomycin—uterine cancer	9.78e-05	0.001	CcSEcCtD
Raloxifene—Bronchitis—Doxorubicin—uterine cancer	9.77e-05	0.001	CcSEcCtD
Raloxifene—Rash—Dactinomycin—uterine cancer	9.7e-05	0.000996	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Etoposide—uterine cancer	9.61e-05	0.000987	CcSEcCtD
Raloxifene—Pain—Etoposide—uterine cancer	9.52e-05	0.000978	CcSEcCtD
Raloxifene—Conjunctivitis—Epirubicin—uterine cancer	9.51e-05	0.000977	CcSEcCtD
Raloxifene—Urinary tract infection—Epirubicin—uterine cancer	9.51e-05	0.000977	CcSEcCtD
Raloxifene—Sweating—Epirubicin—uterine cancer	9.38e-05	0.000963	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—uterine cancer	9.24e-05	0.000949	CcSEcCtD
Raloxifene—Sinusitis—Epirubicin—uterine cancer	9.18e-05	0.000943	CcSEcCtD
Raloxifene—Nausea—Dactinomycin—uterine cancer	9.14e-05	0.000938	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—uterine cancer	9.11e-05	0.000935	CcSEcCtD
Raloxifene—Gastrointestinal pain—Etoposide—uterine cancer	9.1e-05	0.000935	CcSEcCtD
Raloxifene—Rhinitis—Epirubicin—uterine cancer	8.81e-05	0.000904	CcSEcCtD
Raloxifene—Abdominal pain—Etoposide—uterine cancer	8.8e-05	0.000904	CcSEcCtD
Raloxifene—Body temperature increased—Etoposide—uterine cancer	8.8e-05	0.000904	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—uterine cancer	8.8e-05	0.000904	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—uterine cancer	8.8e-05	0.000904	CcSEcCtD
Raloxifene—Hypoaesthesia—Epirubicin—uterine cancer	8.74e-05	0.000898	CcSEcCtD
Raloxifene—Pharyngitis—Epirubicin—uterine cancer	8.72e-05	0.000895	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—uterine cancer	8.68e-05	0.000891	CcSEcCtD
Raloxifene—Urinary tract disorder—Epirubicin—uterine cancer	8.68e-05	0.000891	CcSEcCtD
Raloxifene—Oedema peripheral—Epirubicin—uterine cancer	8.65e-05	0.000889	CcSEcCtD
Raloxifene—Connective tissue disorder—Epirubicin—uterine cancer	8.63e-05	0.000886	CcSEcCtD
Raloxifene—Urethral disorder—Epirubicin—uterine cancer	8.61e-05	0.000884	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—uterine cancer	8.49e-05	0.000872	CcSEcCtD
Raloxifene—Cardiac disorder—Epirubicin—uterine cancer	8.15e-05	0.000837	CcSEcCtD
Raloxifene—Flushing—Epirubicin—uterine cancer	8.15e-05	0.000837	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—uterine cancer	8.15e-05	0.000837	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—uterine cancer	8.09e-05	0.000831	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—uterine cancer	8.07e-05	0.000828	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—uterine cancer	8.03e-05	0.000824	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—uterine cancer	8.01e-05	0.000822	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—uterine cancer	7.99e-05	0.00082	CcSEcCtD
Raloxifene—Angiopathy—Epirubicin—uterine cancer	7.97e-05	0.000818	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—uterine cancer	7.97e-05	0.000818	CcSEcCtD
Raloxifene—Diarrhoea—Etoposide—uterine cancer	7.62e-05	0.000782	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—uterine cancer	7.54e-05	0.000775	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—uterine cancer	7.54e-05	0.000775	CcSEcCtD
Raloxifene—Flatulence—Epirubicin—uterine cancer	7.54e-05	0.000774	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—uterine cancer	7.37e-05	0.000757	CcSEcCtD
Raloxifene—Dizziness—Etoposide—uterine cancer	7.36e-05	0.000756	CcSEcCtD
Raloxifene—Muscle spasms—Epirubicin—uterine cancer	7.35e-05	0.000755	CcSEcCtD
Raloxifene—Vomiting—Etoposide—uterine cancer	7.08e-05	0.000727	CcSEcCtD
Raloxifene—Rash—Etoposide—uterine cancer	7.02e-05	0.000721	CcSEcCtD
Raloxifene—Dermatitis—Etoposide—uterine cancer	7.01e-05	0.00072	CcSEcCtD
Raloxifene—Headache—Etoposide—uterine cancer	6.98e-05	0.000716	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—uterine cancer	6.97e-05	0.000716	CcSEcCtD
Raloxifene—Vertigo—Epirubicin—uterine cancer	6.87e-05	0.000706	CcSEcCtD
Raloxifene—Syncope—Epirubicin—uterine cancer	6.86e-05	0.000704	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—uterine cancer	6.8e-05	0.000699	CcSEcCtD
Raloxifene—Loss of consciousness—Epirubicin—uterine cancer	6.72e-05	0.00069	CcSEcCtD
Raloxifene—Cough—Epirubicin—uterine cancer	6.67e-05	0.000685	CcSEcCtD
Raloxifene—Nausea—Etoposide—uterine cancer	6.61e-05	0.000679	CcSEcCtD
Raloxifene—Chest pain—Epirubicin—uterine cancer	6.51e-05	0.000669	CcSEcCtD
Raloxifene—Arthralgia—Epirubicin—uterine cancer	6.51e-05	0.000669	CcSEcCtD
Raloxifene—Myalgia—Epirubicin—uterine cancer	6.51e-05	0.000669	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	6.47e-05	0.000664	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—uterine cancer	6.36e-05	0.000653	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—uterine cancer	6.35e-05	0.000652	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—uterine cancer	6.22e-05	0.000639	CcSEcCtD
Raloxifene—Infection—Epirubicin—uterine cancer	6.2e-05	0.000637	CcSEcCtD
Raloxifene—Cough—Doxorubicin—uterine cancer	6.17e-05	0.000634	CcSEcCtD
Raloxifene—Shock—Epirubicin—uterine cancer	6.14e-05	0.000631	CcSEcCtD
Raloxifene—Nervous system disorder—Epirubicin—uterine cancer	6.12e-05	0.000629	CcSEcCtD
Raloxifene—Thrombocytopenia—Epirubicin—uterine cancer	6.11e-05	0.000628	CcSEcCtD
Raloxifene—Skin disorder—Epirubicin—uterine cancer	6.06e-05	0.000623	CcSEcCtD
Raloxifene—Hyperhidrosis—Epirubicin—uterine cancer	6.03e-05	0.00062	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—uterine cancer	6.02e-05	0.000619	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—uterine cancer	6.02e-05	0.000619	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—uterine cancer	6.02e-05	0.000619	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	5.98e-05	0.000614	CcSEcCtD
Raloxifene—Infection—Doxorubicin—uterine cancer	5.74e-05	0.000589	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Epirubicin—uterine cancer	5.69e-05	0.000584	CcSEcCtD
Raloxifene—Shock—Doxorubicin—uterine cancer	5.68e-05	0.000583	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—uterine cancer	5.66e-05	0.000582	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—uterine cancer	5.65e-05	0.000581	CcSEcCtD
Raloxifene—Insomnia—Epirubicin—uterine cancer	5.64e-05	0.00058	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—uterine cancer	5.61e-05	0.000576	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—uterine cancer	5.58e-05	0.000573	CcSEcCtD
Raloxifene—Dyspepsia—Epirubicin—uterine cancer	5.49e-05	0.000564	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Epirubicin—uterine cancer	5.39e-05	0.000553	CcSEcCtD
Raloxifene—Pain—Epirubicin—uterine cancer	5.34e-05	0.000548	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.26e-05	0.00054	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—uterine cancer	5.22e-05	0.000536	CcSEcCtD
Raloxifene—Gastrointestinal pain—Epirubicin—uterine cancer	5.1e-05	0.000524	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—uterine cancer	5.08e-05	0.000522	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—uterine cancer	4.99e-05	0.000512	CcSEcCtD
Raloxifene—Pain—Doxorubicin—uterine cancer	4.94e-05	0.000507	CcSEcCtD
Raloxifene—Abdominal pain—Epirubicin—uterine cancer	4.93e-05	0.000507	CcSEcCtD
Raloxifene—Body temperature increased—Epirubicin—uterine cancer	4.93e-05	0.000507	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—uterine cancer	4.72e-05	0.000485	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—uterine cancer	4.57e-05	0.000469	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—uterine cancer	4.57e-05	0.000469	CcSEcCtD
Raloxifene—Diarrhoea—Epirubicin—uterine cancer	4.27e-05	0.000439	CcSEcCtD
Raloxifene—Dizziness—Epirubicin—uterine cancer	4.13e-05	0.000424	CcSEcCtD
Raloxifene—Vomiting—Epirubicin—uterine cancer	3.97e-05	0.000408	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—uterine cancer	3.95e-05	0.000406	CcSEcCtD
Raloxifene—Rash—Epirubicin—uterine cancer	3.94e-05	0.000404	CcSEcCtD
Raloxifene—Dermatitis—Epirubicin—uterine cancer	3.93e-05	0.000404	CcSEcCtD
Raloxifene—Headache—Epirubicin—uterine cancer	3.91e-05	0.000402	CcSEcCtD
Raloxifene—Dizziness—Doxorubicin—uterine cancer	3.82e-05	0.000392	CcSEcCtD
Raloxifene—Nausea—Epirubicin—uterine cancer	3.71e-05	0.000381	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—uterine cancer	3.67e-05	0.000377	CcSEcCtD
Raloxifene—Rash—Doxorubicin—uterine cancer	3.64e-05	0.000374	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—uterine cancer	3.64e-05	0.000374	CcSEcCtD
Raloxifene—Headache—Doxorubicin—uterine cancer	3.62e-05	0.000372	CcSEcCtD
Raloxifene—Nausea—Doxorubicin—uterine cancer	3.43e-05	0.000352	CcSEcCtD
Raloxifene—HTR2B—Signaling Pathways—AKR1B10—uterine cancer	2.41e-05	0.000797	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	2.41e-05	0.000797	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	2.4e-05	0.000794	CbGpPWpGaD
Raloxifene—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	2.37e-05	0.000785	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—NRAS—uterine cancer	2.37e-05	0.000783	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—CDKN2B—uterine cancer	2.36e-05	0.000778	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	2.29e-05	0.000756	CbGpPWpGaD
Raloxifene—AOX1—Disease—CDKN2B—uterine cancer	2.28e-05	0.000752	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.27e-05	0.00075	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—CDKN2B—uterine cancer	2.25e-05	0.000743	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.24e-05	0.000739	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SRD5A2—uterine cancer	2.22e-05	0.000733	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NDUFB11—uterine cancer	2.22e-05	0.000733	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.21e-05	0.000731	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RNF43—uterine cancer	2.19e-05	0.000724	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	2.18e-05	0.00072	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	2.15e-05	0.000712	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—SMAD3—uterine cancer	2.15e-05	0.000711	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—STK11—uterine cancer	2.13e-05	0.000702	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CYP19A1—uterine cancer	2.13e-05	0.000702	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.11e-05	0.000697	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—CCL2—uterine cancer	2.1e-05	0.000693	CbGpPWpGaD
Raloxifene—AOX1—Disease—SMAD3—uterine cancer	2.08e-05	0.000686	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—SMAD3—uterine cancer	2.05e-05	0.000679	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	2.05e-05	0.000677	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—KRAS—uterine cancer	2.04e-05	0.000674	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—TP53—uterine cancer	2.04e-05	0.000672	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKR1B10—uterine cancer	2.01e-05	0.000664	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—INHBA—uterine cancer	2e-05	0.000662	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RNF43—uterine cancer	2e-05	0.000661	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2e-05	0.00066	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	1.99e-05	0.000657	CbGpPWpGaD
Raloxifene—AOX1—Disease—FGFR2—uterine cancer	1.98e-05	0.000655	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—POLD1—uterine cancer	1.96e-05	0.000647	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—CCL2—uterine cancer	1.92e-05	0.000633	CbGpPWpGaD
Raloxifene—AOX1—Disease—MTHFR—uterine cancer	1.91e-05	0.00063	CbGpPWpGaD
Raloxifene—HTR2B—G alpha (q) signalling events—PIK3CA—uterine cancer	1.91e-05	0.00063	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NDUFB11—uterine cancer	1.88e-05	0.00062	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SRD5A2—uterine cancer	1.88e-05	0.00062	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	1.88e-05	0.00062	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—PIK3CA—uterine cancer	1.87e-05	0.000619	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	1.85e-05	0.000613	CbGpPWpGaD
Raloxifene—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	1.85e-05	0.000611	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKR1C1—uterine cancer	1.83e-05	0.000606	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—INHBA—uterine cancer	1.83e-05	0.000604	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.82e-05	0.000603	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—TP53—uterine cancer	1.82e-05	0.000602	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKR1C1—uterine cancer	1.8e-05	0.000596	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—HRAS—uterine cancer	1.73e-05	0.000573	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.72e-05	0.000569	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	1.72e-05	0.000568	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	1.7e-05	0.000563	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.7e-05	0.000561	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—ESR1—uterine cancer	1.68e-05	0.000554	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RNF43—uterine cancer	1.67e-05	0.00055	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—CXCL8—uterine cancer	1.66e-05	0.000548	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKR1C1—uterine cancer	1.65e-05	0.000544	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—RRM2—uterine cancer	1.63e-05	0.00054	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—STAR—uterine cancer	1.6e-05	0.00053	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PTEN—uterine cancer	1.6e-05	0.00053	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKR1B1—uterine cancer	1.6e-05	0.00053	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—MTHFR—uterine cancer	1.6e-05	0.000528	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—DCN—uterine cancer	1.59e-05	0.000524	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PGR—uterine cancer	1.58e-05	0.000523	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	1.58e-05	0.000521	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.56e-05	0.000516	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	1.54e-05	0.000508	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—AKT1—uterine cancer	1.53e-05	0.000506	CbGpPWpGaD
Raloxifene—EBP—Metabolism—EP300—uterine cancer	1.53e-05	0.000505	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—INHBA—uterine cancer	1.52e-05	0.000503	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—CXCL8—uterine cancer	1.51e-05	0.0005	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.51e-05	0.000499	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—EZH2—uterine cancer	1.5e-05	0.000497	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CYP11A1—uterine cancer	1.49e-05	0.000494	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKR1C3—uterine cancer	1.41e-05	0.000466	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—ESR2—uterine cancer	1.39e-05	0.00046	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKR1C3—uterine cancer	1.39e-05	0.000459	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKR1C1—uterine cancer	1.37e-05	0.000453	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKR1B1—uterine cancer	1.36e-05	0.000449	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—STAR—uterine cancer	1.36e-05	0.000449	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PGR—uterine cancer	1.35e-05	0.000447	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.34e-05	0.000443	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—YWHAE—uterine cancer	1.29e-05	0.000427	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.27e-05	0.000421	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKR1C3—uterine cancer	1.27e-05	0.000419	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—POLD1—uterine cancer	1.26e-05	0.000416	CbGpPWpGaD
Raloxifene—AOX1—Disease—ERBB2—uterine cancer	1.24e-05	0.000411	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FBXW7—uterine cancer	1.24e-05	0.000409	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PGR—uterine cancer	1.24e-05	0.000408	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—YWHAE—uterine cancer	1.18e-05	0.000389	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKR1C1—uterine cancer	1.18e-05	0.000389	CbGpPWpGaD
Raloxifene—AOX1—Disease—CDKN1B—uterine cancer	1.15e-05	0.000381	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—CDKN2B—uterine cancer	1.13e-05	0.000375	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PIK3CA—uterine cancer	1.13e-05	0.000374	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FBXW7—uterine cancer	1.13e-05	0.000373	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—STK11—uterine cancer	1.1e-05	0.000363	CbGpPWpGaD
Raloxifene—AOX1—Disease—CTNNB1—uterine cancer	1.09e-05	0.00036	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STK11—uterine cancer	1.08e-05	0.000358	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CCL2—uterine cancer	1.08e-05	0.000356	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—POLD1—uterine cancer	1.07e-05	0.000352	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTEN—uterine cancer	1.06e-05	0.000351	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKR1C3—uterine cancer	1.06e-05	0.000349	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—RRM2—uterine cancer	1.05e-05	0.000347	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—SMAD3—uterine cancer	1.04e-05	0.000342	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.03e-05	0.000341	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PGR—uterine cancer	1.03e-05	0.00034	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—DCN—uterine cancer	1.02e-05	0.000336	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SOCS3—uterine cancer	1.01e-05	0.000335	CbGpPWpGaD
Raloxifene—AOX1—Disease—EP300—uterine cancer	1.01e-05	0.000334	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.01e-05	0.000333	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.01e-05	0.000333	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKR1C1—uterine cancer	9.96e-06	0.000329	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STK11—uterine cancer	9.88e-06	0.000326	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.84e-06	0.000325	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CCL2—uterine cancer	9.83e-06	0.000325	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—YWHAE—uterine cancer	9.82e-06	0.000324	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN2B—uterine cancer	9.7e-06	0.00032	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP11A1—uterine cancer	9.59e-06	0.000317	CbGpPWpGaD
Raloxifene—AOX1—Disease—NRAS—uterine cancer	9.47e-06	0.000313	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF1R—uterine cancer	9.42e-06	0.000311	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FBXW7—uterine cancer	9.41e-06	0.000311	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CXCL8—uterine cancer	9.38e-06	0.00031	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SOCS3—uterine cancer	9.25e-06	0.000306	CbGpPWpGaD
Raloxifene—EBP—Metabolism—AKT1—uterine cancer	9.24e-06	0.000305	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKR1C3—uterine cancer	9.06e-06	0.000299	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTEN—uterine cancer	8.89e-06	0.000294	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—RRM2—uterine cancer	8.88e-06	0.000293	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SMAD3—uterine cancer	8.86e-06	0.000293	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN2B—uterine cancer	8.85e-06	0.000293	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—DCN—uterine cancer	8.62e-06	0.000285	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF1R—uterine cancer	8.6e-06	0.000284	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CXCL8—uterine cancer	8.56e-06	0.000283	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CXCL8—uterine cancer	8.52e-06	0.000281	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—EP300—uterine cancer	8.47e-06	0.00028	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FGFR2—uterine cancer	8.45e-06	0.000279	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—MTHFR—uterine cancer	8.26e-06	0.000273	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STK11—uterine cancer	8.23e-06	0.000272	CbGpPWpGaD
Raloxifene—AOX1—Disease—KRAS—uterine cancer	8.15e-06	0.000269	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP11A1—uterine cancer	8.12e-06	0.000268	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SMAD3—uterine cancer	8.08e-06	0.000267	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CXCL8—uterine cancer	7.77e-06	0.000257	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FGFR2—uterine cancer	7.71e-06	0.000255	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SOCS3—uterine cancer	7.7e-06	0.000255	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKR1C3—uterine cancer	7.67e-06	0.000253	CbGpPWpGaD
Raloxifene—AOX1—Disease—PIK3CA—uterine cancer	7.48e-06	0.000247	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN2B—uterine cancer	7.38e-06	0.000244	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—STAR—uterine cancer	7.29e-06	0.000241	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKR1B1—uterine cancer	7.29e-06	0.000241	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.28e-06	0.00024	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ESR1—uterine cancer	7.23e-06	0.000239	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF1R—uterine cancer	7.16e-06	0.000237	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—STK11—uterine cancer	7.06e-06	0.000233	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP19A1—uterine cancer	7.06e-06	0.000233	CbGpPWpGaD
Raloxifene—AOX1—Disease—HRAS—uterine cancer	6.92e-06	0.000229	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—NRAS—uterine cancer	6.83e-06	0.000226	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SMAD3—uterine cancer	6.73e-06	0.000223	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ESR1—uterine cancer	6.6e-06	0.000218	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGFR2—uterine cancer	6.42e-06	0.000212	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCL2—uterine cancer	6.36e-06	0.00021	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CA—uterine cancer	6.27e-06	0.000207	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—NRAS—uterine cancer	6.24e-06	0.000206	CbGpPWpGaD
Raloxifene—AOX1—Disease—AKT1—uterine cancer	6.11e-06	0.000202	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—AKT1—uterine cancer	6.05e-06	0.0002	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP19A1—uterine cancer	5.98e-06	0.000197	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—STK11—uterine cancer	5.98e-06	0.000197	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CA—uterine cancer	5.95e-06	0.000197	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—uterine cancer	5.88e-06	0.000194	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCL2—uterine cancer	5.81e-06	0.000192	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—POLD1—uterine cancer	5.72e-06	0.000189	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.61e-06	0.000185	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CA—uterine cancer	5.43e-06	0.000179	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CA—uterine cancer	5.4e-06	0.000178	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—uterine cancer	5.37e-06	0.000177	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.35e-06	0.000177	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKR1C1—uterine cancer	5.35e-06	0.000177	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ERBB2—uterine cancer	5.3e-06	0.000175	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—MTHFR—uterine cancer	5.3e-06	0.000175	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AKT1—uterine cancer	5.12e-06	0.000169	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL8—uterine cancer	5.03e-06	0.000166	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HRAS—uterine cancer	5e-06	0.000165	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CA—uterine cancer	4.93e-06	0.000163	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1B—uterine cancer	4.91e-06	0.000162	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKT1—uterine cancer	4.86e-06	0.000161	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ERBB2—uterine cancer	4.84e-06	0.00016	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCL2—uterine cancer	4.84e-06	0.00016	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—RRM2—uterine cancer	4.77e-06	0.000157	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CTNNB1—uterine cancer	4.64e-06	0.000153	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—DCN—uterine cancer	4.63e-06	0.000153	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—uterine cancer	4.59e-06	0.000152	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL8—uterine cancer	4.59e-06	0.000152	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HRAS—uterine cancer	4.56e-06	0.000151	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—uterine cancer	4.52e-06	0.000149	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—MTHFR—uterine cancer	4.49e-06	0.000148	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1B—uterine cancer	4.48e-06	0.000148	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKT1—uterine cancer	4.44e-06	0.000147	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKT1—uterine cancer	4.41e-06	0.000146	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—EP300—uterine cancer	4.38e-06	0.000145	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP11A1—uterine cancer	4.36e-06	0.000144	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EP300—uterine cancer	4.31e-06	0.000143	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CTNNB1—uterine cancer	4.24e-06	0.00014	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—uterine cancer	4.13e-06	0.000136	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKR1C3—uterine cancer	4.12e-06	0.000136	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—uterine cancer	4.09e-06	0.000135	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NRAS—uterine cancer	4.04e-06	0.000133	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB2—uterine cancer	4.03e-06	0.000133	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKT1—uterine cancer	4.03e-06	0.000133	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.96e-06	0.000131	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EP300—uterine cancer	3.94e-06	0.00013	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL8—uterine cancer	3.83e-06	0.000126	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1B—uterine cancer	3.74e-06	0.000123	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—uterine cancer	3.73e-06	0.000123	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NRAS—uterine cancer	3.68e-06	0.000122	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CTNNB1—uterine cancer	3.53e-06	0.000117	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—uterine cancer	3.47e-06	0.000115	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—uterine cancer	3.44e-06	0.000114	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EP300—uterine cancer	3.28e-06	0.000108	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CA—uterine cancer	3.24e-06	0.000107	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.21e-06	0.000106	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—STK11—uterine cancer	3.21e-06	0.000106	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CA—uterine cancer	3.19e-06	0.000105	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—uterine cancer	3.17e-06	0.000105	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—uterine cancer	3.11e-06	0.000103	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—uterine cancer	3.09e-06	0.000102	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NRAS—uterine cancer	3.07e-06	0.000101	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—AKT1—uterine cancer	3.05e-06	0.000101	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HRAS—uterine cancer	2.95e-06	9.76e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—uterine cancer	2.95e-06	9.75e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CA—uterine cancer	2.91e-06	9.62e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—uterine cancer	2.82e-06	9.31e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—EP300—uterine cancer	2.81e-06	9.3e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HRAS—uterine cancer	2.7e-06	8.9e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKT1—uterine cancer	2.65e-06	8.75e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—uterine cancer	2.64e-06	8.73e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKT1—uterine cancer	2.61e-06	8.61e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—uterine cancer	2.5e-06	8.25e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CA—uterine cancer	2.43e-06	8.02e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MTHFR—uterine cancer	2.41e-06	7.96e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—EP300—uterine cancer	2.38e-06	7.87e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKT1—uterine cancer	2.38e-06	7.86e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—uterine cancer	2.35e-06	7.76e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HRAS—uterine cancer	2.25e-06	7.42e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CA—uterine cancer	2.08e-06	6.88e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKT1—uterine cancer	1.98e-06	6.55e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CA—uterine cancer	1.76e-06	5.82e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKT1—uterine cancer	1.7e-06	5.62e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKT1—uterine cancer	1.44e-06	4.76e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—uterine cancer	1.34e-06	4.43e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—EP300—uterine cancer	1.28e-06	4.23e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CA—uterine cancer	9.46e-07	3.13e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKT1—uterine cancer	7.73e-07	2.55e-05	CbGpPWpGaD
